Treatments* | Observed mortality (%) and interactive response between treatments | |||||
---|---|---|---|---|---|---|
Second instar | χ 2 | Responsec | Third instar | χ 2 | Response*** | |
Tracer 800 ppm | 100.00 ± 0.00a** | – | – | 76.67 ± 3.33ab** | – | – |
Tracer 400 ppm | 63.33 ± 3.33 cd | – | – | 50.00 ± 5.77 cd | – | – |
Tracer 200 ppm | 50.00 ± 5.77de | – | – | 33.33 ± 3.33de | – | – |
Sc 1000 IJS | 63.33 ± 3.33 cd | – | – | 46.67 ± 3.34 cd | – | – |
Sc 500 IJS | 33.33 ± 3.33ef | – | – | 33.33 ± 3.33de | – | – |
Sc 200 IJS | 20.00 ± 5.77 fg | – | – | 10.00 ± 5.77ef | – | – |
Sc 100 IJS | 3.33 ± 3.33gh | – | – | 0.00 ± 0.00f | – | – |
Hi 1000 IJS | 60.00 ± 5.77 cd | – | – | 33.33 ± 6.67de | – | – |
Hi 500 IJS | 33.33 ± 3.33ef | – | – | 20.00 ± 5.77ef | – | – |
Hi 200 IJS | 13.33 ± 3.33gh | – | – | 6.67 ± 3.33f | – | – |
Hi 100 IJS | 0.00 ± 0.00 h | – | – | 0.00 ± 0.00f | – | – |
Sc + TR 800 ppm | 100.00 ± 0.00a | 11.28 | Synergistic | 96.67 ± 3.33a | 30.67 | Synergistic |
Sc + TR 400 ppm | 86.67 ± 3.33ab | 17.82 | Synergistic | 70.00 ± 5.77bc | 28.73 | Synergistic |
Sc + TR 200 ppm | 73.33 ± 3.33bc | 17.56 | Synergistic | 50.00 ± 5.77 cd | 12.10 | Synergistic |
Hi + TR 800 ppm | 100.00 ± 0.00a | 12.73 | Synergistic | 86.67 ± 6.68ab | 20.50 | Synergistic |
Hi + TR 400 ppm | 70.00 ± 5.77bc | 10.8 | Synergistic | 76.67 ± 3.33ab | 21.63 | Synergistic |
Hi + TR 200 ppm | 56.67 ± 3.33 cd | 8.89 | Synergistic | 46.67 ± 6.67 cd | 0.20 | Additive |
Control | 0.00 ± 0.00 h | – | 0.00 ± 0.00f | – |